MedTrace Logo

Miglustat on Gaucher Disease Type IIIB

NCT02520934 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-03-29

No results posted yet for this study

Summary

evaluate the combination therapy with Miglustat and enzyme replacement therapy (ERT) on Gaucher disease

Conditions

  • Gaucher Disease

Interventions

DRUG

Miglustat

combine miglustat and ERT to see if neurologic manifestations can be improved

DRUG

ERT

enzyme replacement therapy

Sponsors & Collaborators

  • Actelion

    collaborator INDUSTRY

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Yin-Hsiu Chien, M.D., Ph.D. · National Taiwan University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2017-12-31
Completion
2019-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520934 on ClinicalTrials.gov